Laboratory of Neurosciences and Functional Medicine, International Center for Biomedicine (ICC) and Faculty of Sciences, University of Chile, Santiago, Chile.
Department of Neurology, Faculty of Medicine, University of Chile, Santiago, Chile.
J Alzheimers Dis. 2020;77(2):877-883. doi: 10.3233/JAD-200386.
A major drawback in Alzheimer's disease (AD) is the lack of validated biomarkers for routine clinical diagnostic. We have reported earlier a novel blood biomarker, named Alz-tau®, based on variants of platelet tau. This marker evaluates the ratio of high molecular weight tau (HMWtau) and the low molecular weight (LMWtau) tau.
To analyze a potential novel source of antigen for Alz-tau®, plasma tau, detected by immunoreactivity with the novel monoclonal antibody, tau51.
We evaluated tau variants in plasma precipitated with ammonium sulfate from 36 AD patients and 15 control subjects by western blot with this novel monoclonal antibody.
The HMW/LMWtau ratio was statistically different between AD patients and controls.
Plasma tau variants are suitable to be considered as a novel antigen source for the Alz-tau® biomarker for AD.
阿尔茨海默病（AD）的一个主要缺点是缺乏经过验证的生物标志物用于常规临床诊断。我们之前曾报道过一种新型血液生物标志物，名为 Alz-tau®，它基于血小板 tau 的变体。该标志物评估高分子量 tau（HMWtau）和低分子量（LMWtau）tau 的比值。
分析 Alz-tau®的潜在新型抗原来源，即通过新型单克隆抗体 tau51 的免疫反应检测到的血浆 tau。
我们通过该新型单克隆抗体的 Western blot 评估了用硫酸铵沉淀的 36 名 AD 患者和 15 名对照受试者血浆中的 tau 变体。
AD 患者和对照组之间 HMW/LMWtau 比值存在统计学差异。
血浆 tau 变体适合作为 AD 的 Alz-tau®生物标志物的新型抗原来源。
